Stocks-NTRA-Natera Inc

NTRA Natera Inc

40.39 -1.45 (-3.47%)
Invest
8.34% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
4.4B
Day’s Range
39.94
-
41.48
52W Range
26.03
-
98.39
Volume (3M)
1.44M
Price-Earnings Ratio
-
Revenue
776M
Top Discussions
MarketUpdates
Edited
$NTRA (Natera Inc) Q4 2022 earnings report is expected to be released
23
FEB
REPORTS
Natera Inc Q4 2022 earnings report is expected to be released after market open
Notify me
NTRA
NTRA
Natera Inc
40.39
-1.45
(-3.47%)
Trade
NTRA
Natera Inc
40.31
-1.45 (-3.47%)
Trade
MarketUpdates
$NTRA (Natera Inc) Q4 2022 earnings report is expected to be released
Lorenzo Riccio
Sergio Marcelo Tron
Edited
PRE MARKETS : TOP GAINERS =) $GRAB (Grab Holdings Ltd) + 14.3% =) $VISL (Vislink Technologies Inc) + 13.8% =) $ZIM (ZIM Shipping Services Ltd) + 6.9% =) $EH (EHang Holdings Ltd) + 6.5% =) $NTRA (Natera Inc) + 6.5% TOP LOSERS: =( $TTCF (Tattooed Chef Inc) - 22.6% =( $TBLT (Toughbuilt Industries... Show More
MarketUpdates
Edited
$NTRA (Natera Inc) Q3 2022 earnings report is expected to be released
3
NOV
REPORTS
Natera Inc Q3 2022 earnings report released after market open
NTRA
NTRA
Natera Inc
40.39
-1.45
(-3.47%)
Trade
NTRA
Natera Inc
40.31
-1.45 (-3.47%)
Trade

About Natera Inc

Natera Inc is a clinical genetic testing company based in Austin, Texas, operating across 90 countries worldwide. The firm is engaged in the development of non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. The firm aims to use simple blood-drawing techniques rather than more complex forms of diagnostic testing to help effectively manage disease and inform treatment. Natera Inc was founded in 2004. The firm has a strong focus on women’s health and on pre-natal health in particular. Products that have been developed by Natera include the Spectrum preimplantation genetic test, Anora miscarriage test, Horizon advance carrier screening test, and the Vistara single-gene NIPT. In the area of organ health, the firm has tests for those suffering from diseases of the kidneys, heart, and lungs. In the area of oncology, the firm has developed the Signatera Residual Disease test, the Altera Tumor Genomic profile, and the Empower Hereditary Cancer test. Natera Inc has now seen more than three million of its cfDNA tests performed. The firm has been trading on the NASDAQ since 2015 and is listed under the ticker NTRA. Follow the NTRA share price on eToro by adding this stock to your personalised watchlist.
2.6K
Employees
Austin, Texas, US
HQ
2003
Founded
Stephen Chapman
CEO
Show More

Upcoming Earnings

23
FEB
REPORTS
Natera Inc Q4 2022 earnings report is expected to be released after market open

People Also Bought